Seres Therapeutics, Inc. (MCRB) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 9, 2026
Current Price
$8.73
Price Target
$1.25
Target Range
$1.25 — $1.25
Analyst Rating
Buy
Forward P/E—
Trailing P/E-0.5x
Forward PEG—
Implied Growth-1571.8%
Median Target$1.25
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$1
-85.7%
Consensus
$1
-85.7%
Bull Case
$1
-85.7%
MCRB Price Target Analysis
Updated March 4, 2026As of March 4, 2026, Seres Therapeutics, Inc. (MCRB) has a Wall Street consensus price target of $1.25, based on estimates from 18 covering analysts. With the stock currently trading at $8.73, this represents a potential downside of -85.7%. The company has a market capitalization of $77M.
Analyst price targets range from a low of $1.25 to a high of $1.25, representing a 0% spread in expectations. The median target of $1.25 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 4 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, MCRB trades at a trailing P/E of -0.5x. Analysts expect EPS to grow -1571.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside-51.8%
Avg Forward P/E—
Peers with Coverage2 / 8
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| MCRBSeres Therapeutics, Inc. | $77M | $8.73 | $1.25 | -85.7% | Buy | — | 18 |
 PHGEBiomX Inc. | $76M | $4.20 | — | — | — | — | — |
 ARMPArmata Pharmaceuticals, Inc. | $40M | $10.97 | $9.00 | -18.0% | Buy | — | 4 |
 EVGNEvogene Ltd. | $7M | $0.83 | — | — | — | — | — |
 SYBXSynlogic, Inc. | $7M | $0.59 | — | — | — | — | — |
 TOVXTheriva Biologics, Inc. | $2M | $0.18 | — | — | — | — | — |
 AZTRAzitra, Inc. | $2M | $0.17 | — | — | — | — | — |
 ELABPMGC Holdings Inc. | $766221 | $1.03 | — | — | — | — | — |
Upside Potential Comparison
ARMPMCRBSee MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare MCRB vs AGIO
See how MCRB stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
What is the MCRB stock price target for 2026?
MCRB's consensus price target is $1.25, -85.7% below the current price of $8.73. The 18 analysts tracking MCRB see downside risk at present valuations.
Is MCRB a buy, sell, or hold?
MCRB has a consensus rating of "Buy" based on 18 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $1.25 implies -85.7% downside from current levels.
Is MCRB stock overvalued or undervalued?
MCRB's current price is $8.73 with a consensus target of $1.25 (-85.7% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can MCRB stock go?
The most bullish Wall Street analyst has a price target of $1.25 for MCRB, while the most conservative target is $1.25. The consensus of $1.25 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover MCRB stock?
MCRB is well covered by analysts, with 18 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 3 recommend Hold, and 4 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the MCRB stock forecast?
The 12-month MCRB stock forecast based on 18 Wall Street analysts shows a consensus price target of $1.25, with estimates ranging from $1.25 (bear case) to $1.25 (bull case). The median consensus rating is "Buy".
Should I buy MCRB stock?
Analysts are cautious on MCRB, with 4 Sell ratings and a price target of $1.25 (-85.7% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do MCRB price targets vary so much?
MCRB analyst price targets range from $1.25 to $1.25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $1.25 consensus represents the middle ground.